OKYO Pharma Ltd (OKYO) stock
Close on Nov 10, 2026Market cap $72.42MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Mar 31, 2026
Valuation
- Market cap
- $72.42M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -8.20%
Fundamentals
- EPS, diluted
- -$0.24
- Free cash flow
- -$5.94M
Trading
- Previous close
- $1.28
- Open
- $1.30
- Day's range
- $1.29 – $1.41
- Volume
- 104,756
- Average volume (20 days)
- 62,858
- Beta (5 years)
- 0.32
- 52-week range
- $1.26 – $3.20
- RSI (14 days)
- 46.2
- Volatility (1 year)
- 73.5%
- Relative volume
- 1.14×
- WACC
- 7.4%
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 10, 2026. The S&P 500 is measured by the SPY fund.
| Period | OKYO | S&P 500 | Difference | OKYO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.8% | -3.7% | +0.9 pts | ||
| 3 months | -12.1% | -2.7% | −9.4 pts | ||
| Year to date | -33.3% | +10.8% | −44.2 pts | ||
| 1 year | -48.7% | +11.2% | −59.9 pts | ||
| 3 years | -19.8% | +76.5% | −96.3 pts | -7.1% | +20.8% |
Eight years at a glance
Fiscal years 2019 to 2026, USD
EPS, diluted
Free cash flow
Press releases
Releases OKYO Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About OKYO Pharma
Biological Products, (No Diagnostic Substances)
OKYO Pharma Limited is a biopharmaceutical company focused on developing treatments for ocular surface and anterior segment diseases. Its primary product candidate is urcosimod, formerly known as OK-101, which is in mid-stage development for neuropathic corneal pain and related conditions. It also advances OK-201, an early-stage therapeutic candidate. Because its pipeline remains in testing, the company generates no commercial product sales. Its prospective customers include patients suffering from ocular diseases and the medical professionals who treat them.
Company profile, executives and historyOKYO Pharma stock: common questions
What is OKYO Pharma's stock price?
OKYO closed at $1.38 on Nov 10, 2026, up 7.81% on the day. Over the past 52 weeks it traded between $1.26 and $3.20.
What is OKYO Pharma's market cap?
OKYO Pharma was worth $72.42M at the close on Nov 10, 2026: the share price times the diluted shares outstanding.
What is OKYO's P/E ratio?
OKYO Pharma lost money over fiscal 2026 (diluted EPS -$0.24), so it has no meaningful P/E ratio.
Does OKYO Pharma pay a dividend?
No. OKYO Pharma has not paid a cash dividend over the last twelve months.
How has OKYO stock performed over the past year?
Including dividends, OKYO returned -48.7% over the past year, against +11.2% for the S&P 500.
How many OKYO shares are sold short?
0M shares were sold short at the latest FINRA report, 0.15% of the float, or 1.0 days of average trading volume.
Who are OKYO Pharma's competitors?
Companies most similar to OKYO Pharma by business, industry and size include KLRS, TARS, OCGN, OTLK, VOR.
See a number that looks wrong?